Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DendroCyte Biotech
Concord West / Sydney area, New South Wales, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
DendroCyte developed fully human monoclonal antibodies against CD83 for immune modulation in GVHD and transplant rejection. Lead candidate CBT004 originated from academic collaborations and reached preclinical stage before being licensed to Kira Biotech for further development.
- Therapeutic areas
- Immunology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
TransBio Ltd (technology originator/licensor)University of Queensland, University of California San Francisco (academic collaborators via CRC-BT)
Beyond the preview
Go deeper on DendroCyte Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DendroCyte Biotech.